Galecto, the leading developer of galectin modulators for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and cancer, and PharmAkea, Inc., a privately held San Diego-based pharmaceutical company developing novel small molecules against protein targets involved in fibroproliferative disease, today announced the two companies will merge. Financial terms have not been disclosed. Following completion, the joint company will retain the Galecto name and current senior management team, including Hans Schambye as CEO. Galecto, Inc. will be incorporated in the US and will retain its operating headquarters in Copenhagen, Denmark.
Read the full article: Galecto and PharmAkea Merge to Create Strong Clinical-Stage Company Developing First-in-Class Therapeutics in Fibrosis and Cancer //
Source: https://www.globenewswire.com/news-release/2020/01/07/1966932/0/en/Galecto-and-PharmAkea-Merge-to-Create-Strong-Clinical-Stage-Company-Developing-First-in-Class-Therapeutics-in-Fibrosis-and-Cancer.html